Intended use:
RIDASCREEN® Clostridium difficile Toxin A/B is an enzyme immunoassay for qualitative determination of the Clostridium difficile toxins A and B in human stool specimens and from cultures of toxin-producing Clostridium difficile strains that were previously cultured from stool specimens.
General information:
Clostridioides (Clostridium) difficle infection (CDI) is recognized to be one of the most common causes of nosocomial and antibiotic treatment-associated diarrhea. CDI can occur after disturbance of the gut microbiome by the administration of antibiotics, chemotherapeutic agents, immunosuppressants or proton pump inhibitors, as well as by inflammatory bowel diseases or surgical interventions on the digestive tract. Symptoms of the disease include watery diarrhea with a characteristic foul smell, abdominal pain, fever, leukocytosis, and hypoalbuminemia. In severe cases, ileus, pseudomembranous colitis (PMC), toxic megacolon, intestinal perforation, or sepsis can occur.
The use of multistage testing algorithms has improved overall diagnostic accuracy being of crucial importance for therapy decisions. After initial screening for
C. difficile, testing for toxin A and toxin B is recommended in order to distiguish colonization from infection.
RIDASCREEN® Clostridium difficile Toxin A/B supports CDI detection:
- Direct determination of free C. difficile toxin A and toxin B in the patient specimen
- Use of monoclonal antibodies for outstanding specificity
- Obtains reliable results in combination with RIDASCREEN® Clostridium difficile GDH
Accessories:
Single Components:
- RIDASCREEN® Control – (Negative Control)
- RIDASCREEN® Diluent 1
- RIDASCREEN® Substrate
- RIDASCREEN® Stop
- RIDASCREEN® Wash buffer 10x
| Art. No. | C0801 |
|---|---|
| Test format | ELISA consisting of 96 tests |
Dear customers,
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal eifu.r-biopharm.com/clinic.
